We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01227603
First Posted: October 25, 2010
Last Update Posted: December 10, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
October 22, 2010
October 25, 2010
December 10, 2015
November 2010
March 2011   (Final data collection date for primary outcome measure)
  • Cmax [ Time Frame: Within 48 hours after each treatment ]
    Maximum drug concentration in plasma after dose administration for nifedipine and candesartan
  • AUC(0-tn) [ Time Frame: Within 48 hours after each treatment ]
    AUC from time 0 to the last data point for nifedipine and candesartan
  • C(max) and AUC(0-tn) for nifedipine [ Time Frame: Within 48 hours after each treatment ]
  • C(max) and AUC(0-tn) for candesartan [ Time Frame: Within 48 hours after each treatment ]
Complete list of historical versions of study NCT01227603 on ClinicalTrials.gov Archive Site
  • AUC [ Time Frame: Within 48 hours after each treatment ]
    Area under the plasma concentration vs time curve from zero to infinity after single (first) dose for nifedipine and candesartan
  • Cmax,norm [ Time Frame: Within 48 hours after each treatment ]
    Maximum drug concentration in plasma after dose administration divided by dose (mg) per kg body weight for nifedipine and candesartan
  • AUCnorm [ Time Frame: Within 48 hours after each treatment ]
    Area under the curve divided by dose per kg body weight for nifedipine and candesartan
  • AUC(0-48) [ Time Frame: Within 48 hours after each treatment ]
    AUC from time 0 to time 48 h for nifedipine and candesartan
  • tmax [ Time Frame: Within 48 hours after each treatment ]
    Time to reach maximum drug concentration in plasma after single (first) dose for nifedipine and candesartan
  • t½ [ Time Frame: Within 48 hours after each treatment ]
    Half-life associated with the terminal slope for nifedipine and candesartan
  • MRT [ Time Frame: Within 48 hours after each treatment ]
    Mean residence time for nifedipine and candesartan
  • CL/f [ Time Frame: Within 48 hours after each treatment ]
    Total body clearance of drug from plasma calculated after oral administration (apparent oral clearance) for nifedipine and candesartan
  • Number of participants with adverse events [ Time Frame: Approximately 3.5 months ]
Further pharmakokinetic parameters (AUC, C(max,norm), AUCnorm, AUC(0-48), tmax and t1/2) for nifedipine and candesartan [ Time Frame: Within 48 hours after each treatment ]
Not Provided
Not Provided
 
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design
Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it with the individual drugs
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypertension, Essential
  • Drug: Nifedipine-candesartan FDC (BAY 98-7106)
    Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
  • Drug: Nifedipine GITS (Adalat LA, BAYA1040)
    Single oral dose of 1 tablet of nifedipine GITS 60 mg
  • Drug: Candesartan (Atacand)
    Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
  • Experimental: Nifedipine-candesartan FDC
    Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
    Intervention: Drug: Nifedipine-candesartan FDC (BAY 98-7106)
  • Active Comparator: Nifedipine and candesartan
    Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
    Interventions:
    • Drug: Nifedipine GITS (Adalat LA, BAYA1040)
    • Drug: Candesartan (Atacand)
  • Active Comparator: Nifedipine
    Each subject received one dose of nifedipine GITS 60 mg orally.
    Intervention: Drug: Nifedipine GITS (Adalat LA, BAYA1040)
  • Active Comparator: Candesartan
    Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
    Intervention: Drug: Candesartan (Atacand)
Brendel E, Weimann B, Dietrich H, Froede C, Thomas D. Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Int J Clin Pharmacol Ther. 2013 Sep;51(9):753-62. doi: 10.5414/CP201879.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
July 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male subject
  • Age: 18 to 45 years (inclusive) at the first screening / examination visit
  • Ethnicity: Caucasian
  • Body mass index (BMI): >/=18 and </=29,9 kg/m²

Exclusion Criteria:

  • Systolic blood pressure below 120 or above 145 mmHg
  • Diastolic blood pressure above 95 mmHg
  • Heart rate below 45 or above 95 beats / min
  • Clinically relevant findings in the physical examination
  • Suspicion of drug or alcohol abuse
  • Regular daily consumption of more than 1 L of xanthin-containing beverages
  • Intake of foods or beverages containing grapefruit within 4 weeks before the pre-study examination
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01227603
14027
2010-021966-31 ( EudraCT Number )
No
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top